Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIA-1758 in healthy participants
NCT06406348Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALIA-1758 in Alzheimer's disease (AD) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started May 2024; status: completed.
02
Drugs
ALIA-1758
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06406348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406348.